.png){kind=icon}
返回
Alvimopan
.png){kind=icon}
PRE
AI
DOI：10.2165/00003495-200868140-00006.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Alvimopan, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, is a selective, peripherally acting p-opioid receptor antagonist that is available for short-term use in hospitalized patients who have undergone bowel resection. The efficacy of alvimopan in the management of postoperative ileus has been evaluated in five phase III trials; four conducted in North America and one conducted in Europe/Australasia. Patients who had undergone partial large or small bowel resection surgery with primary anastomosis were randomized to receive alvimopan 12 mg or placebo as a single oral pre-operative dose followed by twice-daily administration for up to 7 days postoperatively. In the five phase III trials, alvimopan was significantly more effective than placebo in reducing the time to recovery of upper and lower gastrointestinal (GI) function, as assessed using a two-component endpoint (GI2) comprising time to tolerance of solid food and first bowel movement. The mean time to reach the GI2 endpoint was 11-26 hours sooner with alvimopan than with placebo. In the phase III trials conducted in North America, the time to writing the hospital discharge order was 13-21 hours sooner with alvimopan than with placebo. Alvimopan did not reduce opicid-induced analgesia and/or increase the amount of opioids administered postoperatively. Short-term alvimopan was generally well tolerated in adults undergoing bowel resection.
Keyword:
MAJOR ABDOMINAL-SURGERY
MU-OPIOID RECEPTOR
PHASE-III TRIAL
POSTOPERATIVE ILEUS
DOUBLE-BLIND
ANTAGONIST
PLACEBO
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
引用论文
分享收藏分享收藏
Alvimopan, a novel, peripherally acting g opioid antagonist - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus.png)
ANNALS OF SURGERY
OAAI
ANNALS OF SURGERYIF6.4
OAAI分享收藏
查看更多内容